Valuation: Innoviva, Inc.

Market Cap 158.25Cr 138.99Cr 129.26Cr 118.61Cr 222.86Cr 15TCr 226.29Cr 1.53TCr 599.66Cr 7.49TCr 594.06Cr 581.25Cr 26TCr P/E 2026 *
6.42x
P/E 2027 * 9.37x
Enterprise Value 106.84Cr 94Cr 87Cr 80Cr 150.46Cr 10TCr 152.78Cr 1.04TCr 404.86Cr 5.06TCr 401.08Cr 392.43Cr 17TCr EV / Sales 2026 *
2.43x
EV / Sales 2027 * 1.76x
Free-Float
99.01%
Yield 2026 *
-
Yield 2027 * -
1 day+1.13%
1 week-1.24%
Current month-5.59%
1 month-9.04%
3 months-9.04%
6 months+9.84%
Current year+7.25%
1 week 21.05
Extreme 21.05
21.72
1 month 21.05
Extreme 21.05
23.72
Current year 19
Extreme 19
25.14
1 year 16.52
Extreme 16.52
25.14
3 years 12.22
Extreme 12.22
25.14
5 years 10.64
Extreme 10.64
25.14
10 years 7.58
Extreme 7.58
25.14
Manager TitleAgeSince
Chief Executive Officer 42 20/05/2020
Director of Finance/CFO 60 21/08/2023
Investor Relations Contact - 01/09/2025
Director TitleAgeSince
Director/Board Member 75 12/02/2018
Director/Board Member 66 12/02/2018
Director/Board Member 42 19/05/2025
Date Insider Type Main position Quantity % Market Cap.
20/05/26 Tax

Controller/Auditor

-1,127 0.0015%
20/05/26 Tax

Chief Financial Officer

-559 0.0008%
20/05/26 Tax

Chief Executive Officer

-1,130 0.0015%
Change 5-day change 1-year change 3-year change Capi.($)
+1.13%-1.24%+14.53%+62.92% 158.25Cr
+0.86%+1.43%+47.17%+163.68% 1,06700Cr
+1.59%+4.09%+56.51%+52.50% 63TCr
+0.95%+1.91%+36.30%+82.78% 46TCr
+1.39%+8.65%+38.30%+32.28% 35TCr
+1.45%+4.66%+38.03%+41.97% 30TCr
+1.61%+4.15%+19.50%+20.50% 26TCr
+1.13%-0.99%-28.02%-38.98% 22TCr
+1.22%+2.66%+22.66%+59.87% 20TCr
-1.18%-3.70%+11.28%+67.52% 16TCr
Average +0.80%+1.07%+25.63%+54.51% 36.45TCr
Weighted average by Cap. +0.61%+1.95%+36.44%+79.42%

Financials

2026 *2027 *
Net sales 44Cr 39Cr 36Cr 33Cr 62Cr 4.24TCr 63Cr 427.31Cr 166.94Cr 2.09TCr 165.38Cr 161.82Cr 7.21TCr 49Cr 43Cr 40Cr 36Cr 68Cr 4.68TCr 70Cr 471.45Cr 184.19Cr 2.3TCr 182.47Cr 178.54Cr 7.96TCr
Net income 29Cr 25Cr 23Cr 21Cr 40Cr 2.75TCr 41Cr 277.34Cr 108.35Cr 1.35TCr 107.34Cr 105.03Cr 4.68TCr 19Cr 16Cr 15Cr 14Cr 26Cr 1.78TCr 26Cr 179.55Cr 70Cr 876.41Cr 69Cr 68Cr 3.03TCr
Net Debt -51Cr -45Cr -42Cr -39Cr -72Cr -4.95TCr -74Cr -498.61Cr -194.8Cr -2.43TCr -192.98Cr -188.82Cr -8.42TCr -73Cr -64Cr -59Cr -55Cr -102.59Cr -7.02TCr -104.17Cr -706.54Cr -276.04Cr -3.45TCr -273.46Cr -267.57Cr -12TCr
Logo Innoviva, Inc.
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Employees
159
Date Price Change Volume
24/26/24 $21.44 +1.13% 5,50,443
23/26/23 $21.20 -1.07% 9,42,291
22/26/22 $21.43 -0.70% 4,82,091
21/26/21 $21.58 +1.41% 6,06,559
20/26/20 $21.28 -1.98% 7,05,621
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
21.44USD
Average target price
35.50USD
Spread / Average Target
+65.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INVA Stock